United Therapeutics, which operates a large manufacturing facility in RTP, is expanding its research and development into organ manufacturing by acquiring Minnesota-based Miromatrix Medical.
Read More
A federal appeals court won’t upend Morrisville-based Liquidia’s loss in a patent dispute with United Therapeutics that threatens to stall the U.S. launch of Liquidia’s Yutrepia treatment for pulmonary arterial hypertension.
Read More
United Therapeutics is building a $500 million manufacturing facility in Research Triangle Park to expand production of a drug-device combination product that received approval by the U.S. Food and Drug Administration last year.
Read More
United Therapeutics Corporation earlier this week unveiled its new net zero energy distribution center located on the company’s co-headquarters campus in Research Triangle Park.
Read More
Biopharma firm Liquidia has struck a deal for $100 million in capital that it says “extends [its] cash runway” and provides funds for launch of its lead product that targets pulmonary arterial hypertension if and when patent litigation over the treatment is resolved
Read More
Triangle drug firm Liquidia’s legal battle with United Therapeutics over patent issues and a new drug to treat pulmonary arterial hypertension is still headed for a court trial in March, but the company’s CEO is encouraged by a “partial judgment” in ongoing legal proceedings.
Read More
One month after a favorable ruling in a patent dispute, Morrisville-based Liquidia has gained tentative approval from the U.S. Food and Drug Administration for Yutrepia, its inhalation powder for treating pulmonary arterial hypertension. Here are the details.
Read More
United Therapeutics has filed a new drug application to the U.S. FDA, and asked for priority review.
Read More
United Therapeutics, which has a big operation in RTP, is paying $105 million to acquire a voucher that it says will accelerate its New Drug Application process with the FDA.
Read More
